Deutsche Bank Downgrades MAP Pharmaceuticals (MAPP) to Hold; Doesn't Expect Other Bids
Tweet
Share
E-mailGet Alerts MAPP Hot Sheet
Price: $21.40 --0%
Rating Summary:
2 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 10 | New: 14
Rating Summary:
2 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 10 | New: 14
Join SI Premium – FREE
Deutsche Bank downgraded MAP Pharmaceuticals (NASDAQ: MAPP) from Buy to Hold following takeover deal. The firm doesn't expect other bids.
For an analyst ratings summary and ratings history on MAP Pharmaceuticals click here. For more ratings news on MAP Pharmaceuticals click here.
Shares of MAP Pharmaceuticals closed at $24.75 yesterday.
For an analyst ratings summary and ratings history on MAP Pharmaceuticals click here. For more ratings news on MAP Pharmaceuticals click here.
Shares of MAP Pharmaceuticals closed at $24.75 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Upgrades Sirius XM Radio (SIRI) to Neutral, 'risk-reward is balanced at prevailing levels'
- BofA Securities Downgrades CEMEX (CX) to Neutral
- Jefferies Downgrades Hang Zhou Great Star Industrial Co (002444:CH) to Hold
Create E-mail Alert Related Categories
DowngradesRelated Entities
Deutsche BankSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
